 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (January 2023) |
 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2014[1] |
| Founder | Alex Zhavoronkov |
| Headquarters | Science Park, |
Number of locations | 6 |
Area served | Artificial intelligence, deep learning |
Key people | Alex Zhavoronkov, PhD, Feng Ren, PhD, Alex Aliper, PhD, Michelle Chen, PhD, Nirav Jhaveri, MBA, Jimmy Lin, PhD, Quentin Vanhaelen, PhD |
| Services | Drug discovery |
| Website | insilico |
Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong,[2] and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.[3][4][5]
- ^ Cite error: The named reference
awas invoked but never defined (see the help page). - ^ Saharan, Vikas Anand (2022). Computer Aided Pharmaceutics and Drug Delivery. Springer. p. 363-64.
- ^ "Insilico Medicine launches a drug discovery platform ALS.AI". EurekAlert!. 1 June 2017. Retrieved 28 August 2017.
- ^ Al Idrus A (16 August 2017). "GlaxoSmithKline taps Baltimore's Insilico for AI-based drug discovery". FierceBiotech. Retrieved 28 August 2017.
- ^ "InSilico Medicine Company Profile". PitchBook. Retrieved 28 August 2017.